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This project had led, thus far, to the development of four academic papers.  
The first of these was published in Nature Biotechnology and the second 
was published in Cell Stem Cell.  The third paper has recently been 
submitted to a peer-reviewed journal, while the fourth is currently being 
revised in preparation for submission to a peer-reviewed journal later in 
the year.  In addition, this project led to the development of a new website 
(www.stemcellstates.net) that provides public access to information on 
state stem cell grants awarded between 2005 and 2009. 
 
Copies of the two published papers and working drafts of the two other 
papers are attached to this report.  
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effects of state-funded stem cell research is 
both timely and useful.
The database that forms the basis for the 
analysis described here contains the title, 
principal investigator, institution, abstract 
and amount for each grant awarded by 
the agency overseeing stem cell research 
funding in these six states (Supplementary 
Methods). In all, between December 2005 
when New Jersey awarded the first state stem 
cell grants and the end of 2009, the six stem 
cell states awarded nearly 750 grants totaling 
just over $1.25 billion. The scale of these 
programs varies substantially, ranging from 
the roughly $15 million awarded by Illinois 
and New Jersey to the $1.02 billion awarded 
by California. On a per capita basis, funding 
awarded through the end of 2009 ranges 
from just over $1 in Illinois to nearly $28 in 
California (Table 1).
States funding stem cell research 
can choose to support several different 
activities, ranging from investigator-
initiated research grants to new facilities 
to workforce development. To investigate 
how states prioritized these various types 
of funding, each grant was classified by 
its primary purpose (Supplementary 
Methods). Research grants and support for 
scientific infrastructure were the two largest 
categories, accounting for more than 90% 
of all state stem cell funding (Table 1). The 
infrastructure category was dominated by 
the $271 million California awarded for the 
construction of 12 major stem cell research 
facilities, although several other states also 
dedicated a substantial portion of their 
funding to infrastructure, such as shared 
equipment or core laboratories. In contrast 
to supporting basic investigator-initiated 
research, spending money on infrastructure 
is a classic state economic development 
approach, but, in these cases, spending 
was motivated, at least in part, by the need 
to create separate laboratories to facilitate 
research on unapproved hESC lines.
The restrictions on federal funding for 
hESC research instituted by former President 
George W. Bush were an important rationale 
behind the adoption of most state stem cell 
programs, yet it is not clear to what extent 
state programs focused on hESC research 
generally or hESC research not eligible for 
federal funding more specifically. To address 
these questions, each research grant awarded 
through the end of 2009 was analyzed to 
assess if funded research used hESCs and, 
if applicable, appeared ineligible for federal 
funding under the Bush Administration 
rules (Supplementary Methods). The 
percentage of grants that supported hESC 
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informed debate regarding stem cell tourism 
and for protecting potentially vulnerable 
individuals.
Note: Supplementary information is available on the 
Nature Biotechnology website.
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these state funding programs. Existing 
work on state stem cell policy has focused 
on identifying policy differences between 
various jurisdictions3,4, assessing the impact 
of state decisions to support or restrict hESC 
science5–7 and examining the role of states 
in governing controversial science8,9. The 
analysis reported here extends this literature 
though use of a novel data set of the grants 
these states have awarded. These data provide 
insight into how states have prioritized their 
funding, including the extent to which they 
have supported hESC research generally 
and hESC research not eligible for federal 
funding during the Bush Administration 
more specifically, as well as the extent to 
which these states have drawn new scientists 
into the field. The underlying data have been 
publicly released on a new website (http://
www.stemcellstates.net) designed to facilitate 
additional analysis of state-funded stem 
cell science and improve public awareness 
of these programs. Given ongoing legal 
uncertainties surrounding federal funding 
of hESC research and the likelihood that 
voters, at least in California, will be asked to 
approve additional state stem cell funding in 
the future, understanding and evaluating the 
Tracking and assessing the rise of 
state-funded stem cell research
To the Editor:
The editorial in your October issue1 
highlights the legal challenges to new 
guidelines issued by the US National 
Institutes of Health (NIH) in July 2009 for the 
federal funding of human embryonic stem 
cell (hESC) research. In the eight-year period 
preceding these most recent NIH guidelines, 
only a small number of cell lines could be 
studied with federal funds. During this time, 
six states—California, Connecticut, Illinois, 
Maryland, New Jersey and New York—took 
on a role typically played by the NIH and 
created funding programs specifically 
designed to support stem cell research, 
including hESC research. These are not the 
first state programs to fund scientific research 
but their commitment to basic research is 
atypical, as most state science and technology 
programs have focused on science closer to 
commercialization2. Although the state stem 
cell programs differ, they each share at least 
two goals: advancing promising science, 
including research not eligible for federal 
funding during the Bush Administration, and 
returning economic benefits to their state.
In this article, we report an initial 
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cell research could complement their existing 
research programs.
These data also permit a more nuanced 
comparison between state stem cell funding 
and NIH stem cell funding than has 
previously been available (Fig. 1). Total state 
funding for all types of stem cell research has 
risen rapidly since grants were first awarded 
in 2005, but states still spend less than half of 
what the NIH spends each year on stem cell 
research. The situation is different for hESC 
research, as state funding for hESC research 
grants first exceeded comparable NIH 
funding in 2007 and equaled or exceeded it in 
2008 and 2009.
Considered together, these data and 
analyses indicate that state funding for stem 
cell research has grown into a substantial 
enterprise that has provided funding on a 
scale comparable to the NIH. Although states 
vary in the degree to which they have focused 
on hESC research, as a whole, state funding 
for hESC research has been substantial, 
exceeding, in cumulative terms, NIH funding 
for this research between 2005 and 2009. 
Most state hESC funding appears to have 
supported research also eligible for federal 
funding during the Bush Administration. 
This finding is surprising, given the 
explicit intent of several state programs to 
preferentially support science not eligible for 
federal funding, but likely reflects the nature 
of the grant proposals state agencies received, 
particularly given the number of grants states 
awarded to scientists relatively new to the 
field of hESC research.
In the light of the recent change in 
federal stem cell policy and the ongoing 
economic downturn, the future of state 
unable to access the raw materials or acquire 
the intellectual property rights required to do 
so. Alternatively, these findings could simply 
reflect scientific interest. The discovery of 
induced pluripotent stem cells11 may, for 
instance, have reduced scientific interest in 
the derivation of new hESC lines. Finally, 
these findings may reflect a preference on the 
part of scientists to use well-established and 
well-studied hESC lines. This last explanation 
may be particularly relevant for new scientists 
entering the field of hESC research, as using 
recognized cell lines may give their initial 
research efforts greater credibility.
In addition to supporting research not 
eligible for federal funding, focused state 
programs might serve to draw new scientists 
into the field of stem cell research. To 
evaluate this potential impact, the recent NIH 
funding portfolio of each scientist receiving a 
state stem cell grant with a primary purpose 
of research was examined (Supplementary 
Methods). Although most scientists had 
received NIH funding, a substantial number 
(ranging from 42% in California to 71% in 
Maryland) had not received NIH funding 
for stem cell research (Table 1). Similar, 
but more pronounced, results are observed 
when the NIH funding portfolio of scientists 
receiving state funding for hESC research is 
examined, as only a small minority of these 
scientists also had NIH grants supporting 
hESC research. Given the importance of 
NIH funding for biomedical research in the 
United States, these results suggest that the 
existence of state funding programs for stem 
cell research has drawn many new scientists 
into the field of stem cell research, or at least 
encouraged scientists to consider how stem 
research varied substantially among these 
states (Table 1). Large majorities of the 
research grants awarded in Connecticut 
and California supported studies involving 
hESCs, whereas only a minority of grants 
supported hESC research in the other states. 
These disparities likely reflect differences 
in the types of stem cell scientists present in 
these states as well as priorities of the various 
state funding bodies.
Only a subset of grants for hESC 
research supported science that was 
clearly ineligible for NIH funding during 
the Bush Administration. California and 
Connecticut focused the most on this sort 
of research—which typically involved the 
derivation of new hESC lines or the use 
of newer unapproved cell lines—but even 
in these states fewer than a fifth of grants 
went to clearly ineligible research. Many 
scientists indicated plans to use existing 
hESC lines but did not specify which lines 
they planned to use. Given evidence that a 
handful of approved cell lines account for a 
large proportion of the hESC lines actually 
distributed to scientists and an even larger 
share of published literature10, most of these 
projects probably used approved hESC lines. 
In some cases, however, scientists may have 
chosen to use ineligible cell lines but not 
clearly indicated these plans. Thus, the share 
of grants reported here as clearly ineligible 
for NIH funding should be viewed as a lower 
bound on the amount of research each state 
funded that was ineligible for federal funding.
Several factors could explain the relatively 
small share of grants that went toward clearly 
ineligible research. Some scientists who 
wished to pursue this research may have been 
Table 1  The scale and prioritization of state stem cell funding programsa
State program
Grants and funding California Connecticut Illinois Maryland New Jersey New York
Year first grants awarded 2006 2006 2006 2007 2005 2008




N/A N/A N/A $600 million/ 
11 years
Number of grants awarded 329 69 17 140 35 158
Funding awarded ($ millions) 1,024 40 15 54 15 121
Funding per capitab($) 28 11 1 10 2 6
Research prioritizationc
Percentage of funding for research 58% 76% 100% 93% 64% 61%
Percentage of funding for infrastructure 31% 24% 0% 0% 36% 34%
Percentage of grants for hESC research 75% 97% 35% 42% 21% 21%
Percentage of grants clearly not NIH eligible 18% 16% 12% 3% 6% 0%
NIH funding status of state grant recipientsd
Percentage of state PIs without NIH stem cell funding 42% 61% 65% 71% 61% 49%
Percentage of state hESC PIs without NIH hESC funding 77% 91% 67% 79% 100% 66%
aIncludes grants awarded through the end of 2009. bPer capita funding based on state population from US Census Bureau 2009 Population Estimates. chESC prioritization analysis includes 
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stem cell programs, as well as similar state 
programs supporting other areas of science, 
is uncertain. The analysis here suggests 
that state stem cell funding programs 
are sufficiently large and established that 
simply ending the programs, at least in 
the absence of substantial investment in 
the field by other funding sources, could 
have deleterious effects. Such action would 
fail to capitalize on the initial efforts of 
scientists who have been drawn to the field 
of stem cell research by state programs and 
leave many stem cell scientists suddenly 
searching for funding to continue their 
research.
Large-scale state funding for basic 
research is a relatively new phenomenon, 
and many questions remain about 
the impact of these programs on the 
development of scientific fields and the 
careers of scientists. The influence of state 
funding programs on the distribution 
of research publications, the acquisition 
of future external funding, the creation 
of new companies and the translation 
of basic research into medical practice, 
for instance, are important unanswered 
questions. Similarly, comparing state 
funding programs with federal funding 
programs as well as foundations could offer 
new insight into the relative priorities of 
different funding bodies and the extent 
to which their funding portfolios overlap 
or are distinct. We hope the analysis 
presented here and the public release of the 
underlying database will inspire additional 
analysis of state science funding programs 
generally and state-funded stem cell science 
in particular.
Note: Supplementary information is available on the 
Nature Biotechnology website.
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Figure 1  Comparing state and NIH stem cell funding. (a) Total amount of all NIH stem cell grants and 
all stem cell grants awarded by the six states. (b) Total amount of all NIH and state hESC research 
grants. Only grants with a primary purpose of research are included. State funding is by calendar year. 




















































































We report on the launch of version 7 of 
the Human Protein Atlas with subcellular 
localization data and expression data 
for all major human tissues and organs. 
A milestone has been achieved with the 
inclusion of expression data for >50% of the 
human protein-coding genes. The main new 
feature of the release is an attempt towards 
a knowledge-based portal, including an 
annotated protein expression feature for 
protein targets analyzed with two or more 
antibodies, and the establishment of the main 
subcellular localization of protein targets.
In 2005, the first version of the Human 
Protein Atlas (http://www.proteinatlas.
org/) was released with protein profile 
data based on immunohistochemistry on 
tissue microarrays covering 48 different 
human tissues and organs, including kidney, 
liver, heart, brain and pancreas1. The first 
version included data from 718 antibodies 
corresponding to 650 human protein-coding 
genes. High-resolution images were published 
along with annotation of the presence or 
absence of a particular protein target in all 
represented tissues. The 2005 Human Protein 
Atlas also contained information regarding 
protein profiles from 20 different types of 
human cancer, including breast, colorectal, 
lung and prostate cancer. The data in the 
portal were made available freely both for 
academia and industry without restrictions or 
password protection. In 2007, the portal was 
extended to also include subcellular profiling 
data2 using immunofluorescence-based 
confocal microscopy in three human cancer 
cell lines of different (glial, mesenchymal and 
epithelial) origin. More data have been added 
to the portal every year since the first release3 
and version 6, launched in March 2010, 
contained 11,274 antibodies corresponding to 
8,489 protein-coding genes. This entire effort 
depends heavily on the availability of good 
quality antibodies, and recently a community-
based portal, Antibodypedia (http://www.
antibodypedia.org/), has been launched to 
allow antibodies from different providers to 
be listed and compared4,5, although the main 
source of information so far comes from 
the providers’ own validation data, not by 
independent third-party users. At present, 
the Antibodypedia contains close to 100,000 
antibodies, corresponding to >70% of the 
protein-coding genes in humans.
An important objective has now been 
reached with the inclusion of 10,118 protein-
coding genes corresponding to >50% of the 
19,559 human entries as defined by UniProt, 
including only entries with evidence at protein 
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A survey of U.S. stem cell scientists shows that uncertainty following the legal challenge to the Obama
Administration’s hESC research policy has negative scientific and economic impacts and affects a range
of stem cell scientists, not just those working with hESCs. The international implications of these results
are also discussed.One consequence of the ethical contro-
versy inspired by human embryonic
stem cell (hESC) research has been an
atypically uncertain policy environment.
For stem cell scientists in the United
States and, in particular, those scientists
working with hESCs, frequent policy
changes have made the years since these
cells were first derived (Thomson et al.,
1998) something of a roller coaster.
Similar challenges have faced stem cell
scientists around the world, as numerous
countries in Europe, South America, and
Asia, as well as the European Union as
a whole, have engaged in protracted
debates over stem cell policy (see Gott-
weis et al., 2009 for a discussion of global
stem cell policy debates).
In the United States, scientists have
faced several hESC policy changes (re-
viewed in Gottweis, 2010). First, following
a legal review, the Clinton Administration
adopted a policy in August 2000 that
permitted federal funding of hESC
research, but not the derivation of new
hESC lines (65 Fed. Reg. 51,975). Before
any grants could be funded, however,
the Bush Administration put this policy
on hold and President Bush announced
a new policy in August 2001 limiting
federal funding to research using hESC
lines derived prior to the date of his
speech. Although this policy remained in
place for nearly eight years, uncertainty
persisted. Congress, for instance, twice
passed legislation to overturn the
temporal restrictions central to the policy,
yetPresidentBushvetoedboth thesebills.
During the Bush Administration, stem
cell policy was frequently addressed at
the state level with some states support-
ing stem cell research and others restrict-
ing it, creating one of the many heteroge-132 Cell Stem Cell 8, February 4, 2011 ª2011neous ‘‘policy patchworks’’ that have
become typical of the field, even on an
international scale (Caulfield et al., 2009).
Supportive state policies aimed to pro-
vide a workaround for scientists affected
by federal funding restrictions, yet even
these programs were plagued by uncer-
tainty, as legal challenges and state
budget problems hindered their imple-
mentation. California’s stem cell program,
for instance, was delayed for nearly 2 and
a half years by litigation, causing difficul-
ties for scientists considering starting
new stem cell projects or moving to new
institutions. California’s funding is now
flowing and the state has awarded more
than $1 billion, yet the future of this
program remains uncertain as the end of
its 10 year term approaches (see Karmali
et al., 2010 for a recent review of state
stem cell funding).
More recently, at the federal level, the
Obama Administration adopted a new
stem cell research policy in July 2009
(74 Fed. Reg. 32,170), only to throw the
field into chaos when scientists realized
the limited number of hESC lines that
had been eligible for federal funding
during the Bush Administration were no
longer on the approved list and needed
to be reevaluated. Key hESC lines,
including the two most heavily studied
lines, have since been added to the
registry, but not before months of uncer-
tainty during which some scientists were
placed in the awkward position of
choosing to delay projects until their
preferred cell lines were approved or
switching to other lines and facing the
delays associated with reoptimizing
experimental protocols.
A legal challenge filed following the
promulgation of the Obama Administra-Elsevier Inc.tion’s policy adds additional uncertainty
to the field. This challenge claims that
the Obama Administration’s policy vio-
lates the Dickey-Wicker Amendment,
a rider added to the Department of Health
and Human Services appropriations bill
each year since fiscal year 1996. This
lawsuit received minimal attention from
the scientific community until August 23,
2010 when U.S. District Court Judge
Royce Lamberth granted the plaintiffs’
request for a preliminary injunction
barring implementation of the Obama
Administration’s policy pending the out-
come of the court case. This ruling led
the NIH to suspend funding and review
of pending hESC research proposals as
well as evaluation of new hESC lines
(see Gottweis, 2010 for a general discus-
sion, U.S. NIH Notice NOT-OD-10-126
for details). The Obama Administration
appealed and on September 9, 2010 the
U.S. Court of Appeals for the District of
Columbia enjoined the preliminary injunc-
tion, allowing the NIH to resume funding
hESC research while the case proceeded.
Both the ultimate outcome of this case
and the length of time before the outcome
is known are uncertain, placing some
scientists in the situation of checking the
news each day to determine the legal
status of their research (Harmon, 2010).
Although the ultimate outcome of the
litigation will depend on statutory interpre-
tation of the Dickey-Wicker Amendment,
much of the legal wrangling thus far has
focused on the issue of potential harm to
stem cell scientists associated with these
policy changes. In his ruling announcing
the injunction, Judge Lamberth con-
cluded that the plaintiffs—two adult
stem cell scientists—would ‘‘suffer irrepa-





























Impact of temporary fotcapmInab  policy uncertainty
Figure 1. Impact of the Temporary Funding Ban and Ongoing Policy Uncertainty by Type of
Stem Cells Used
Stem cell scientists’ views of the impact of the temporary ban on federal funding on their research (A) and
the impact of the ongoing policy uncertainty on their future research plans (B) are shown, grouped by the
type of stem cells scientists use in their research. n = 370 respondents (85 who use only nonpluripotent
stem cells [Non-PSCs], 79 who use pluripotent stem cells but not hESCs [PSCs but not hESCs], and
206 who use hESCs). Respondents were provided with a brief description of the ongoing legal proceed-
ings and then asked about the impact of the temporary funding ban on their research and ongoing policy
uncertainty on their research plans. Chi-square testing found that differences among these groups were
statistically significant (ban: chi-statistic = 75.1, df = 6, p = 3.6e14; policy uncertainty: chi-statistic = 91.7,
df = 6, p = 1.3e17). See Table S1 for text of the survey questions.
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Foruminjunction’’ due to increased competition
for limited federal research funding, while
the ruling ‘‘would not seriously harm ESC
researchers because the injunction would
simply preserve the status quo and would
not interfere with their ability to obtain
private funding for their research’’ (U.S.
District Court for the District of Columbia).
In its appeal, the Obama Administration
disagreed, arguing that the harm to the
plaintiffs was speculative and
‘‘cannot outweigh the disruption or ruin
of research into promising treatments for
the most debilitating illnesses and
injuries’’ caused by the preliminary injunc-
tion (U.S. Court of Appeals for the D.C.
Circuit).
Despite this ongoing legal debate in the
United States and the prevalence of
policy uncertainty in this field around the
world, relatively few empirical studies
address these issues. In order to begin
to fill this gap, this Forum reports
responses from 370 individuals who
participated in a survey of U.S. stem cell
scientists in November 2010 and
assesses the reported impact of the
preliminary injunction and ongoing uncer-
tainty about the future of federal funding
for hESC research on their work (see
Supplemental Information available online
for details of survey design and analysis
strategies employed). These data show
that both Judge Lamberth’s ruling and
the ongoing uncertainty have had a sub-
stantial impact on stem cell scientists
and illustrate that this impact extendsbeyond hESC scientists to affect, often
negatively, a larger group of stem cell
scientists.
Scientists reported the impact of the
temporary funding ban and ongoing
policy uncertainty on a four-point scale
ranging from no impact to substantial
impact and scientists who indicated that
they experienced an impact were asked
to briefly explain the impact (see Table
S1 for the text of the survey questions).
Figure 1 shows the responses for these
questions for three groups: (1) Scientists
who use hESCs in their research; (2)
scientists who do not use hESCS but do
use human induced pluripotent stem cells
(IPSCs), nonhuman embryonic stem cells,
or non-human IPSCs in their research;
and (3) scientists who use only nonpluri-
potent stem cells in their research. Scien-
tists working with hESCs were most likely
to report being impacted by the tempo-
rary ban. Approximately 75% of these
scientists reported an impact and 24% re-
ported a substantial impact. In addition,
41% of stem cell scientists not working
with hESCs reported that the temporary
ban impacted their research, and 13% of
these respondents indicated this impact
was either moderate or substantial.
Notably, among the 50 non-hESC scien-
tists who indicated they were impacted
by the ban and answered a free-text
question describing this impact, negative
impacts were much more common than
the positive impact envisioned by Judge
Lamberth in his ruling. In total, 45 ofCell Stem Cell 8these non-hESC scientist respondents
described negative impacts (e.g., hin-
dered collaborations, blocked review of
funding applications, and challenges re-
cruiting), two described positive impacts
(enhanced attractiveness and fundability
of non-hESC research), and three could
not be classified as clearly positive or
negative.
The impact of ongoing policy uncer-
tainty on stem cell scientists’ research
plans was more substantial than the
impact of the temporary funding ban.
Just under half of the hESC scientists
who participated in the survey indicated
that this uncertainty has a substantial
impact on their research plans and
another 28% of these scientists said
this uncertainty has a moderate impact.
In addition, 47% of scientists who
worked with pluripotent stem cells, but
not hESCs, and 22% of scientists
working only with nonpluripotent stem
cells also indicated that this uncertainty
has either a moderate or substantial
impact on their research plans.
To better understand the nature of
these impacts, the responses of the 235
scientists who provided a free-text
description of the impact of policy uncer-
tainty on their research plans were
analyzed (see Supplemental Information
for details). Table 1 shows the ten most
frequent impacts mentioned by these
respondents (see Table S2 for example
responses for each impact). Many of
these reported impacts affected the type
or quality of science that these scientists
conducted, by, for instance, changing
the types of stem cells they used in their
research. The single most common
impact—mentioned by 50 respon-
dents—was delaying plans to begin
hESC research or start a new hESC
research project. Over 80% of the
respondents reporting this impact did
not currently work with hESCs but were
considering transitioning their research
to use these cells. In addition, 34 scien-
tists identified transitioning away from or
reducing reliance on hESCs as an impact
of the ongoing uncertainty. Not all of these
scientists specified the type of research to
which they were transitioning, but 13 indi-
cated that they were shifting their
research to human IPSCs or nonhuman
embryonic stem cells, even if, as might
be the case, these were less appropriate
tools for their specific research questions., February 4, 2011 ª2011 Elsevier Inc. 133







Delay plans to begin hESC research or new hESC project 50 18%
Impede ongoing research 44 16%
Limit future funding options 37 13%
Transition away from or reduce reliance on hESCs 34 12%
Disrupt long-term planning (e.g., hiring decisions) 24 9%
Adopt suboptimal research designs 19 7%
Delay or abandon NIH proposals 14 5%
Alter NIH proposals to avoid hESC research 11 4%
Consider relocation 9 3%
Disrupt collaborations 9 3%
The ten most common impacts reported by stem cell scientists are shown, based on qualitative
analysis of free-text responses describing the impact of ongoing policy uncertainty on scientists’
research plans. See Table S2 for example responses for each impact.
Cell Stem Cell
ForumForty-four scientists indicated that policy
uncertainty was impeding ongoing re-
search. This impact took several forms,
including increased cost and administra-
tive burden associated with returning to
the Bush Administration practice of
segregating federally and nonfederally
funded hESC research or conducting
research in duplicate with both hESCs
and IPSCs. Also notable, given the on-
going economic downturn and the inclu-
sion of research funding as part of the
financial stimulus plan, were economic
impacts noted by some scientists. In
particular, 24 scientists indicated that
the ongoing policy uncertainty made it
difficult to engage in long-term planning,
such as decisions to hire postdoctoral
researchers, graduate students, and
research technicians. In addition, a small
number of stem cell scientists indicated
that the ongoing uncertainty was leading
them to consider relocating tomore favor-
able research environments. Similar to the
impact of the temporary ban discussed
above, there was little evidence that
non-hESC scientists found this uncer-
tainty beneficial. Only 4 of the 87 respond-
ing non-hESC scientists who provided
a free-text description of the impact
described it as beneficial to their research
through increased prominence or funding
opportunities. In contrast, 6 of these non-
hESC scientists described a negative
impact on their research through, for
example, increased competition (presum-
ably from hESC scientists moving to non-
hESC work) or spillover effects between
various types of stem cell research. In134 Cell Stem Cell 8, February 4, 2011 ª2011addition, numerous non-hESC scientists
described other negative impacts, such
as hindered collaborations and changes
to their future research plans. These
results indicate that policy uncertainty
surrounding hESC research in the United
States has both negative scientific and
economic impacts and affects scientists
working with all types of stem cells.
The results reported here provide one
of the first systematic estimates of the
impact of the short-lived preliminary
injunction and ongoing policy uncertainty
on the conduct of stem cell research in
the United States. The results conflict
with Judge Lamberth’s assertion that
his preliminary injunction would have
little impact and suggest that rather
than simply preserving the status quo,
this injunction substantively changed
the playing field for many hESC scientists
in the United States as well as a lesser
number of stem cell scientists working
with other cell types. In addition, these
results indicate the broad impact of
ongoing policy uncertainty on the
research plans of stem cell scientists.
These results suggest that, regardless of
the ultimate outcome of the ongoing
legal proceedings, Judge Lamberth’s
ruling has already been a substantial
victory for opponents of hESC research.
The ruling increased the policy uncer-
tainty in the field at a time when many
scientists believed President Obama’s
policy offered respite from a lengthy
period of restricted funding and has
encouraged scientists to reconsider plans
to use hESCs in their research or acceler-Elsevier Inc.ated plans to transition away from these
cells. More surprisingly, these results
also suggest that the ruling and ongoing
policy uncertainty have negatively
affected non-hESC stem cell research,
a finding that likely runs counter to the
plaintiffs’ hopes.
While this analysis focused on stem cell
scientists in the United States, presum-
ably the scientists most affected by the
ongoing litigation, the nature of some of
the impacts reported—notably the dis-
ruption of collaborative research proj-
ects—suggests that this particular case
of policy uncertainty might also be
affecting stem cell scientists around the
world. Policy heterogeneity has previ-
ously been identified as a concern that
could hinder collaborative stem cell
research (Mathews et al., 2006), and this
analysis suggests that policy uncer-
tainty—essentially a form of policy hetero-
geneity over time—should also be consid-
ered a potential barrier to collaboration.
Policy uncertainty may also hinder
academic/industry collaborations and
limit access to venture funding, hindering
commercialization of hESC-based tech-
nologies (Harvey, 2009). Although the
current U.S. situation, where a lawsuit
threatens the legality of all federal hESC
funding, is a particularly dramatic case,
scientific uncertainty can arise in other
situations, and this analysis also high-
lights the types of impacts policymakers
around the world should consider when
crafting stem cell policies.
In addition to arguing for a reassess-
ment of the concept of harm to stem cell
scientists in the ongoing legal proceed-
ings, these findings suggest more broadly
that lawmakers, both in the United States
and around the world, aiming to support
stem cell research should strive for poli-
cies that, to the extent possible, reduce
uncertainty facing stem cell scientists. In
the United States, passing legislation to
provide a clear legal basis for the federal
funding of hESC research, thus pre-emp-
ting the ongoing legal proceedings and
reducing the field’s reliance on executive
action, would meet these goals. For indi-
vidual U.S. states as well as other jurisdic-
tions around the world developing stem
cell funding policies, adopting long-term
programs rather than relying on yearly
authorizations would seem a wise
strategy. Given the divisiveness of the
debate over hESC research and the
Cell Stem Cell
Forumhistory of policymaking in other morally
charged areas, however, such policy
certainty will likely prove difficult to
achieve and some degree of uncertainty
may be unavoidable. For this reason,
hESC scientists should prepare to face
continued policy fluctuations, legal chal-
lenges, and other hurdles to their research
in the future.
SUPPLEMENTAL INFORMATION
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During most of the last decade, human embryonic stem cell (hESC) research in the 
United States has been regulated by an atypically heterogeneous policy environment, 
sometimes termed a “regulatory patchwork” (Knowles, 2004).  This environment emerged 
following the August 2001 decision of President Bush to limit federal research funding for this 
controversial, but potentially promising, field to a small number of hESC lines derived prior to 
the date of his announcement (Bush, 2001).  Despite substantial debate, this policy remained 
essentially unchanged for the duration of George W. Bush’s presidency.  Following his election, 
President Obama announced a new policy in early 2009.  This policy permits federal funding for 
research on a wider range of hESC lines, although some practices, such as the derivation of 
new hESC lines are still restricted.  A lawsuit challenging the legality of the Obama 
Administration’s guidelines was filed in 2009 and substantial uncertainty over the future of 
federal funding continues to persist as this lawsuit works its way through the courts. 
In the years following the announcement of the Bush Administration’s federal funding 
restrictions, numerous states adopted policies designed to support hESC research and stem 
cell research more broadly, while other states have taken steps to explicitly restrict research in 
this field.  Some, but not all, of the supportive states, have taken the unusual step of providing 
state funding to support stem cell research.  New Jersey became the first state to commit state 
funding to this field in early 2004.  California followed New Jersey with a large commitment of $3 
billion over ten years and, because of scale of its program, now dominates the policy landscape.   
Since the approval of California’s program by state voters in November 2004, Connecticut, 
Maryland, New York and Illinois have also committed varying amounts of state funding to stem 
cell research.  All told, six states have pledged approximately $3.75 billion to support this field 
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over the next decade.  Thus far, these states have awarded in excess of $1 billion with 
additional funding slated for the next few years (Karmali et al., 2010). 
These state policies have many goals.  They hope to counteract restrictions on federal 
funding for hESC research and accelerate potentially life-saving research.  In addition, state 
policymakers hope that state-specific research support will yield localized economic benefits.  
These economic development goals are visible in the economic impact assessments (Baker 
and Deal, 2004; Seneca and Irving, 2005) that supporters of these stem cell policies 
commissioned and used to help sell the programs to undecided voters and legislators.  These 
reports enumerate a range of potential economic benefits, including reduced health care costs, 
the recruitment of scientists and biotechnology firms and the return of licensing revenue to the 
state. 
 Because funding investigator-initiated basic research has largely been a federal 
responsibility in the United States, states seeking to support stem cell research had to develop 
novel infrastructure to do so.  Within a few years, each of the six states developed a set of 
policies to administer a scientific research grant program.  These policies ranged from the 
creation of peer review mechanisms and ethical oversight committees to the wording of 
contractual agreements between the state and its grantees.  Not surprisingly, given the different 
approaches through which stem cell policy was enacted and the differing experiences and 
circumstances of each state, substantial variability exists among the policies adopted by the six 
states.  This research views this concurrent policy development and resultant policy variability 
as a sort of natural experiment and seeks to understand how this variability influences scientists’ 
behavior.  Specifically, this article seeks to exploit variability in states’ licensing and revenue 
sharing policies for intellectual property derived from state-funded stem cell research to add to 






















































































































































































































Principal Investigator  0.01  ‐0.08  ‐0.07  ‐0.07 
Female  ‐0.14**  ‐0.06  ‐0.01  ‐0.01 
Highest Degree since 2000  0.06  0.06  ‐0.01  ‐0.002 
Highest Degree between 1990 and 1999  0.08  0.09  0.04  0.05 
Previous Stem Cell Patents  0.14**  0.23**  0.24**  0.23** 
Previous Non‐Stem Cell Patents  0.11**  0.03  ‐0.01  ‐0.02 
New to Stem Cell Research  .03  0.07  0.04  0.04 
Uses human embryonic stem cells  .02  ‐0.04  0.02  0.01 
State Revenue Sharing    0.17*    0.08 
No State Revenue Sharing    0.05    0.04 
Constant  0.32**  0.35**  0.35**  0.33** 
         
N  160  62  143  143 
R2  0.23  0.41  0.19  0.20 
Table 2 – Ordinary lease squares regression analysis of scientists’ entrepreneurial activity 
** P < 0.01, * P < 0.05 
 
  Model 1 shows that only a few of the independent variables are significant predictors of 
scientists’ entrepreneurial activity associated with their federally funded stem cell research.  
Only previous patent filing is positively associated with the entrepreneurship index, with 
scientists having filed a stem cell related patent application in the last three years scoring 0.14 
higher on the entrepreneurship index and scientists having filed a non‐stem cell related patent 
application in the last three years scoring 0.11 higher on the index.  In addition the gender 
dummy variable was significant.  In this model, female respondents scored 0.14 lower on the 
entrepreneurship index than male respondents.  The results are similar when the revenue 
sharing variables are added in Model 2.  As noted previously, the sample size drops 
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substantially for this analysis as only scientists with both federal and state stem cell funding are 
included.  In this analysis, the gender dummy variable and the variable for previous non‐stem‐
cell related patent applications are no longer significant.  Notably, the state revenue sharing 
variable entered the model significantly.  Scientists who indicated that they believed that their 
state funded stem cell research was subject to revenue sharing requirements scored 0.17 
higher on the entrepreneurship index for their federally funded stem cell research.  This 
suggests that the presence of state revenue sharing requirements encourages scientists who 
have the option to shift their more entrepreneurial research to funding sources with fewer 
restrictions. 
  The analysis shown in models 3 and 4 focusing on entrepreneurial activity associated 
with state funded stem cell research were similar, although fewer variables were significant.  In 
the simple model without the revenue sharing variables, only the dummy variable indicating 
whether or not the respondent had submitted a stem cell related patent application was 
significant.  Unlike the case of the entrepreneurship index for federally funding research, when 
the revenue sharing variables were added to this analysis, they were not statistically significant.  
When model 4 is run limited to scientists with both state and federal stem cell funding, the 
revenue sharing variables remain insignificant (not shown).  This suggests that the presence of 
state revenue sharing restrictions is causing scientists with both state and federal funding to 
conduct more entrepreneurial science while not substantially affecting then entrepreneurial 
nature of their state funded stem cell research. 
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Conclusions 
The research presented in this article has examined the entrepreneurial activity 
associated with state and federal funding for stem cell research.  In general, scientists with 
state and federal stem cell funding report similar levels of entrepreneurial activity, such as 
collaborations with industry and filing of patent applications.  Differences in entrepreneurial 
activity were observed, however, when focusing the analysis on scientists who had both state 
and federal stem cell funding.  These scientists were significantly less likely to engage in 
entrepreneurial activities with their state funded state cell research than they were with their 
federally funded stem cell research.  Regression analysis illustrated that these scientists’ beliefs 
that their state funded stem cell research was subject to revenue sharing requirements was a 
significant predictor of their entrepreneurial activity associated with their federally funded 
research.  This suggests that policy choices, such as the implementation of revenue sharing 
requirements, can have a substantial effect on scientists’ entrepreneurial activities. 
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